Recombinant factor VIIa in massive postpartum haemorrhage

Int J Obstet Anesth. 2007 Jan;16(1):29-34. doi: 10.1016/j.ijoa.2006.09.001. Epub 2006 Nov 27.

Abstract

Massive postpartum haemorrhage is a major cause of maternal and fetal morbidity and mortality. Management mainstays include transfusion therapy, uterotonic agents and surgery. The "off label" use of recombinant activated factor VII appears to have an evolving role in the management of massive postpartum haemorrhage refractory to conventional treatments. The current literature is reviewed.

Publication types

  • Review

MeSH terms

  • Coagulants / adverse effects
  • Coagulants / therapeutic use*
  • Factor VII / adverse effects
  • Factor VII / therapeutic use*
  • Factor VIIa
  • Female
  • Humans
  • Jehovah's Witnesses
  • Obstetric Surgical Procedures / adverse effects
  • Postpartum Hemorrhage / drug therapy*
  • Pregnancy
  • Recombinant Proteins / adverse effects
  • Recombinant Proteins / therapeutic use
  • Time Factors
  • Uterine Inertia / drug therapy

Substances

  • Coagulants
  • Recombinant Proteins
  • Factor VII
  • recombinant FVIIa
  • Factor VIIa